On April 15, Life Technologies (NASDAQ:LIFE) ended its strategic review, which culminated in a sale of the company to Thermo Fisher Scientific (NYSE:TMO). At $76 per share (in cash), the takeover represents a 12% premium to Life's close on April 12, and a premium of over 30% relative to where the company was trading prior to confirming that it was in the process of conducting a strategic review. From the perspective of Life Technologies, the price seems fair; the $76 offer represents an all-time high for Life, and at the company's current trading price of just over $73, shares have returned nearly 50% so far in 2013. Few analysts or existing Life investors have expressed opposition...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|